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Abstract 
The cyclodimerization (twinnig) of β-hydroxy acid amides of type 1 under ‘direct amide 
cyclization’ (DAC), conditions is described. Although other coupling methods also gave 
moderate results, best yields were obtained via DAC, reaching 88% for the cyclodimer 
10. In all cases, when starting with racemic material, only the trans-substituted 
cyclodepsipeptides were isolated. Simple molecular modeling revealed that the formation 
of the cyclodimer is thermodynamically slightly more favorable than that of the 
cyclomonomer. The proposal that cyclodimer formation is preferred because of the 
presence of intramolecular H-bonds could not be confirmed by X-ray crystallography. 
The influence of substituents, both in the amino acid and in the hydroxy acid moieties, 
was also studied. It is shown, that cyclodimerization was successful only when the 
hydroxy acid moiety is α,α-disubstituted. 
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1. Introduction 
 
In a recent paper,1 we reported that amides 1, when subjected to the conditions of the 
‘direct amide cyclization’ reaction,2-9 yielded only the dimerized product 3. The 14-
membered cyclodepsipeptide 3 was isolated as the sole product and none of the expected 
7-membered monomer 2 could be detected (Scheme 1). 
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Scheme 1 
 
In order to explain this unexpected result we investigated some other lactonization 
methods with derivatives of 1, including that described by Richard et al.,10 which, in the 
case of ethyl 6-hydroxyhexanoates, had resulted in the formation of 7-membered 
lactones. Again, in all experiments with derivatives of 1, where a defined product could 
be isolated, we obtained only the dimeric product 3.  
Cyclic 14-membered depsipeptides with the same ring skeleton as 3 have been known 
since the 1960’s, and the dimerization process is not as surprising as it seems at first. 
Since the discovery, isolation and identification of serratamolide (4: R = H, R’ = 
(CH2)6CH3, Scheme 2) from Serratia marcescens in 1961,11 the proof of its antibiotic 
activity,12 and  its first total synthesis by Shemyakin et al.,13 the interest in depsipeptides 
containing β-hydroxy acids has increased significantly, mainly because of their antibiotic 
properties. The other important biological role of the same compound, is its use as a 
surface-active agent under the name of serrawettin W1,14 and it has been patented for the 
use as a pesticide as well.15 
 
The synthetic pathways to serratamolide (4) and its derivatives are numerous, but the 
approaches can be divided into three main groups: classical ring closure of linear 
 3 
precursors, usually by lactam bond formation (54), ring enlargement (674), and 
cyclization by twinning (84) (Scheme 2). 
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Scheme 2 
 
The main feature of the last-mentioned method is that the cyclization is performed with 
the monomeric linear precursor, and the twinning, or cyclodimerization, takes place 
during the course of the reaction. Some basic theories have been offered as an 
explanation of this dimerization. One of the most popular proposal states that it is mainly 
due to intermolecular hydrogen bonding between carbonyl and amine groups that are  
formed during the reaction.16,17 In the case of 4, the two planar trans-amide groups  form 
a trans-annular hydrogen bond (intramolecular) and thus favor the formation of a 14-
membered ring. That no monomeric product was formed in the reaction can probably be 
explained by the fact that such an intramolecular interaction would not be possible within 
a 7-membered ring. However, the contribution of hydrogen bonding tends to be 
overestimated as some dimerizations also take place in polar solvents, which could 
interfere with such an intramolecular interaction.17 Another theory proposed by 
Ovchinnikov et al.18 is that the cyclization is preceded by a linear polycondensation, 
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which results in linear dimers and oligomers, which, under the conditions of high 
dilution, may undergo cyclization. The extent of the ring closure is determined 
principally by the most stable conformation of a given linear peptide, being close to that 
of the cyclic product. On the other hand, the formation of trimers seems to be statistically 
unfavorable. 
 
The reason for the preferred dimerization in the case of 1 is most probably a defined 
conformation of the linear precursor and the stability of the transition state. Another 
reason could be the rigidity of the amide bond in 1, although the reactions with an ester 
analogue of compound 1 showed that again oligomerization occurred to give tri- and 
tetrameric structures of the β-hydroxy acid.1 Therefore, most probably the dimerization is 
not a result of the amide bond rigidity. 
 
In order to further investigate the cyclodimerization of dipeptide analogues of type 1 
under the conditions  of the ‘direct amide cyclization’ we synthesized some other amide 
precursors, which differ in the substitution in the α-amino acid as well as in the β-
hydroxy acid moiety, including chiral compounds. Furthermore, we tried to get some 
information from computer modeling of key compounds. 
 
2. Results and discussion 
 
It is known from previous experiments5-7,19,20 that dipeptides of type 1, in which the two 
methyl groups in the amino acid residue are replaced by a cyclopentane ring (i.e. the 
compounds contain 1-aminocyclopentane carboxylic acid instead of 1-aminoisobutyric 
acid (Aib)), react in a very similar way to 1. Therefore, our first target was amide 9, 
which was conveniently prepared by the coupling of 3-hydroxy-2,2-dimethylpropanoic 
acid with N,N-dimethyl-1-azaspiro[2.4]hept-1-en-2-amine in analogy to Ref. 1 
(‘azirine/oxazolone method’; see also Ref. 21). After bubbling HCl gas through a solution 
of 9 in toluene (20 mM) at 100 oC for 4 min, 88% of the corresponding  14-membered 
cyclodepsipeptide 10 was obtained (Scheme 3). Similarly, the linear racemic dipeptides 
11a,b22 carrying two different substituents on the C(α) atom, were also synthesized by 
 5 
the ‘azirine/oxazolone method’. ‘Direct amide cyclization’ of 11b yielded, upon 
cyclization, 68% of the dimeric meso-compound 12 as the sole product. 
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Scheme 3 
 
This was clearly indicated by the 1H and 13C spectra, which show only one set of signals. 
The structures of 10 and 12 were established by X-ray crystallography (Figure 1). 
a) 
 
b) 
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Figure 1. ORTEP plots23 of the molecular structures of  a) 10 and b) 12 (50% probability 
ellipsoids, arbitrary numbering of atoms). 
 
The backbones of the two structures are very similar and also resemble the structures of 
the previously  reported tetramethyl analogue 3.1 In the case of 10, the molecule sits 
about a crystallographic centre of inversion. The cyclopentane ring has an envelope 
conformation with the spiro C-atom as the envelope flap. Each amide NH group forms an 
intermolecular hydrogen bond with a lactone carbonyl O-atom of an adjacent molecule. 
The molecular symmetry results in there being two parallel hydrogen bonds running in 
opposite directions between each molecule. These interactions link the molecules into 
extended double-bridged chains which run parallel to the [1 0 0] direction. Taken 
individually, the repeat unit in the chain generated by one of the interactions has a graph 
set motif24 of C(5). The pair of hydrogen bonds linking two adjacent molecules forms a 
loop with a graph set motif of R2,2(16). In the case of 12, the space group is 
centrosymmetric and the molecule again sits about a crystallographic centre of inversion. 
Therefore, 12 has the (7RS, 7’SR)-configuration, i.e.  12 is the trans-isomer. The 
hydrogen bonding pattern in the crystals of 12 is the same as for 10. 
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The nature of the cyclodimerization in the case of 11 is remarkable. Starting with a 
racemic precursor 11, one would expect that a mixture of cis- and trans-substituted 
cyclodimers would be obtained, but only the trans-isomer 12 has been formed in 68% 
yield. 
 
As mentioned before, factors that might influence the cyclization are not only the type, 
but also the number of substituents in the amino acid moiety. Therefore, a cyclization 
experiment was carried out with an analogue of 11, which contains a monosubstituted 
amino acid. Direct amide cyclization was not an option in this case, since the 
intermediate oxazolone does not form smoothly in the case of monosubstituted 
substrates25. Therefore, we used the base catalyzed lactonization described in Ref. 10. 
When a solution of the enantiomerically pure  13 was heated in toluene (200 mM) in the 
presence of 1 equiv of NaH, the 14-membered cyclic depsipeptide trans-14 was obtained 
as the only isolable product in 44% yield. In order to compare the configurations of the 
two stereogenic centers, the analogous cyclization  was performed with a racemic starting 
material, i.e. methyl ester 15 (Scheme 4). Surprisingly, a single cyclodepsipeptide was 
again obtained in 24% yield and was identical with trans-14 in all respects. 
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Scheme 4 
 
The 1H NMR spectrum of the cyclized product obtained from 13  using a shift reagent 
(Pirkle reagent) and HPLC on a chiral adsorbent (Chiracel OD-H, Merck Whelk-O 1) 
showed the presence of only one compound, which was identical with the product 
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obtained from the cyclization of 15. X-ray crystallography of both products confirmed 
their identical structure and proved that the benzyl groups are trans-oriented (Figure 2). 
The space group of trans-14 is centrosymmetric and the molecule sits about a 
crystallographic centre of inversion, so the two stereogenic centres have inverted 
configurations, i.e. (7RS, 7’SR). The hydrogen bonding pattern is again analogous to that 
of 12 and 10. 
 
As the precursor 13 was optically active ([α]25,D= +44.6, c = 1, CHCl3), an inversion of 
the configuration at one of the stereogenic centers has taken place during the cyclization 
step. With the aim of avoiding this inversion, another cyclization was attempted with the 
corresponding free hydroxy acid 16, which was obtained from the basic hydrolysis of 13. 
Cyclization of both  rac-16 and (S)-16 was achieved under neutral conditions using I2 as 
a catalyst,26 which has previously proven to be efficient for the synthesis of depsipeptide 
3.1 The product obtained from rac-16 was again the meso-compound trans-14a, while the 
enantiomerically pure acid (S)-16, obtained by a milder hydrolysis of its methyl ester 17, 
yielded also only one cyclodepsipeptide, namely (S,S)-14 (Scheme 5). 
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Analytical HPLC of both of these compounds on a chiral column (Whelk-O 1 column, 
hexane/EtOH 10:1) clearly shows two different peaks with retention times of 10.8 and 
10.9 min, respectively. The HPLC diagram of a mixture of the two compounds under the 
same conditions also showed two peaks, proving once more their different structure. 
Furthermore, it was shown, that (S,S)-14 is optically active. For this reason, we expected 
that it is the cis-isomer with the (S,S)-configuration, which was subsequently proven by 
X-ray crystallography (Figure 2). 
a) 
 
 
b) 
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Figure 2. ORTEP plots23 of the molecular structures of  a) trans-14 and b) molecule A of 
(S,S)-14 (50% probability ellipsoids, arbitrary numbering of atoms). 
 
In the crystal structure of (S,S)-14, there are two symmetry-independent molecules A and 
B in the asymmetric unit, but the conformations of the two molecules are almost 
identical.  The space group permits the compound in the crystal to be enantiomerically 
pure, but the absolute configuration of the molecule has not been determined.  The 
enantiomer used in the refinement was based on the expected (S)-configuration of each 
chiral centre in the molecule.  The crystal is merohedrally twinned, with twin operator [1 
0 0 / 0 -1 0 / 0 0 -1] and the major twin domain has a volume fraction of 0.640(1).  Each 
amide group in molecule A forms an intermolecular hydrogen bond with an amide O-
atom of an adjacent molecule A.  This results in there being two parallel hydrogen bonds 
running in opposite directions between each molecule.  The interactions link the 
molecules into extended double-bridged ···A···A···A··· chains which run parallel to the 
[1 0 0] direction. Taken individually, the repeat unit in the chain generated by one of the 
interactions has a graph set motif
24
 of C(4).  The pair of hydrogen bonds linking two 
adjacent molecules forms a loop with a graph set motif of R2,2(18). The molecules of 
type B are similarly linked into extended double-bridged ···B···B···B··· chains which 
also run parallel to the [1 0 0] direction.  
 
From these results it could be concluded that monosubstituted amino acids in amides of 
type 1 do not prevent the cyclodimerization. Next, the influence of the disubstitution of 
C(α) of the β-hydroxy acid  should be investigated and, therefore, analogous dipeptides 
with a α-monosubstituted β-hydroxy acid were synthesized and subjected to cyclization 
procedures. Tropic acid (3-hydroxy-2-phenylpropanoic acid) turned out to be an 
interesting starting material for this study. Thus, amides 18a and 18b were prepared by 
coupling tropic acid with 2,2,N,N-tetramethyl-2H-azirin-3-amine and  2,2,N-trimethyl-N-
phenyl-2H-azirin-3-amine, respectively, and subjected to the conditions of the ‘direct 
amide cyclization’. Surprisingly, the cyclization failed and only traces of the 
corresponding 1,3-oxazol-5(4H)-one were identified in the crude reaction mixture by IR 
and NMR spectroscopy. Column chromatography led to no identifiable products. 
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Furthermore, the corresponding ethyl ester 19, derived from either of the amides 18 by 
treatment with HCl gas in EtOH, did not yield cyclic products upon treatment with NaH. 
Other lactonization procedures, proven to be successful in the case of amide derivatives,1 
also failed to give the desired cyclic depsipeptide in this case (Scheme 6). 
 
When tropic acid was coupled with L-phenylalanine t-butylester.HCl,  amide 20 was 
obtained as a mixture of two diastereoisomers. They were separated on a Whelk-O 1 
preparative HPLC column, and we attempted to cyclize each of them, in order to 
determine the stereospecificity of the NaH cyclization. Unfortunately both the racemic 
and the enantiomerically pure substrates failed to give cyclic depsipeptides (Scheme 6). 
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Scheme 6 
 
The reason for the failure of cyclization of  18-20 could be a steric hindrance of the 
phenyl group in the α-position or its electronic effect. To examine this possibility, 3-
hydroxy-2-methyl-2-phenylpropanoic acid was prepared27 and coupled with the 
corresponding 2H-azirin-3-amines to give 21a,b. The third explanation could be that the 
cyclization is thermodynamically unfavorable when the substrate is monosubstituted in 
the α-position of the β-hydroxy acid moiety. Therefore, α-benzyl-β-hydroxypropanoic 
acid and  β-hydroxyisobutyric acid were synthesized according to known procedures28 
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and coupled with 2,2,N,N-tetramethyl-2H-azirin-3-amine to give amides 22 and 23, 
respectively, as substrates for the cyclization (Scheme 7). 
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Scheme 7 
 
As expected, amide 21b cyclized under DAC conditions to yield the 14-membered 
cyclodepsipeptide 24 in moderate yield. This result suggests that amides of type 18/21 
bearing a phenyl group at C(α) of the hydroxy acids do cyclize when α,α-disubstituted, 
i.e. the phenyl group in 18 was not the reason for its failure to give cyclic products. 
Compound 24 was isolated as a colorless solid, which showed only one set of signals in 
the NMR spectra. Therefore it could be suggested that only one stereoisomer, as a meso-
compound, has been obtained. Careful crystallization from a mixture of 
toluene/acetonitrile/acetone gave crystals suitable for X-ray crystallography. The 
molecular structure of 24 is depicted in Figure 3, showing that again the trans-isomer has 
been obtained. 
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Figure 3. ORTEP plot23 of the molecular structure of  24 (50% probability ellipsoids, 
arbitrary numbering of atoms). 
 
Since the space group is centrosymmetric, 24 is a meso-compound.  The molecule sits 
about a crystallographic centre of inversion, so therefore has the (4RS,4'SR)-
configuration. Remarkably, the amide groups are not involved in any hydrogen bonds.  
Although amide O-atoms in adjacent molecules appear to be positioned correctly to 
accept a hydrogen bond from the amide H-atom, the H···O distance of 2.98 Å is much 
too long for it to be considered a hydrogen bond.  This is probably the result of molecular 
bulk preventing the molecules packing close enough together for intermolecular 
hydrogen bonds to form. 
 
Amides 22 and 23 failed to cyclize under the DAC reaction conditions, as was the case 
with 18. Upon monitoring the reaction of 18 by IR spectroscopy, the formation of the 
corresponding 1,3-oxazol-5(4H)-one 25, which is the expected intermediate in the 
cyclization reaction, was observed (strong absorption at 1820-1830 cm-1),29 and after 
addition of methanol to the reaction mixture,  methyl ester 26 was isolated in 58% yield 
(Scheme 8). 
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The formation of a methyl ester and the IR spectra strongly suggest the presence of a 1,3-
oxazol-5(4H)-one as an intermediate. It seems that the oxazolone formation and 
dehydration in the case of 18 are competitive reactions. In order to get an indication of 
which reaction takes place first, a similar set of experiments was carried out with benzyl 
derivative 22. Upon bubbling HCl gas through a solution of 22 in toluene/methanol 
(20%), the only product obtained was the corresponding hydroxy ester 27 (Scheme 9). 
When the reaction was carried out under the conditions described for 18, i.e. oxazolone 
formation with HCl gas in toluene (monitoring by IR, increasing absorption at 1826 cm-1) 
and addition of methanol after saturation, the dehydrated ester 28 and the dehydrated 
amide 29 were obtained in addition to 27 (Scheme 9). 
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Scheme 9 
 
This result suggests that when the reaction is carried out in the presence of a nucleophile, 
such as methanol, oxazolone 26 is formed first and is immediately  transformed into the 
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corresponding hydroxy ester 27. On the other hand, in the absence of a nucleophile, the 
intermediate oxazolone 26 eliminates water, leading to 2-vinyl oxazolones and thus 
preventing further cyclization. The formation of 28 and 29 can be explained by the 
competitive ring opening of 26 by the nucleophiles methanol and N-methylaniline, 
respectively.  This result is an additional indication that the cyclodimerization process 
occurs via an oxazolone intermediate. 
 
Another variation of the starting materials for the direct amide cyclization (DAC) is the 
insertion of aromatic β-hydroxy acids or β-hydroxycycloalkane carboxylic acids. The 
first of these derivatives, salicylamide 30, was obtained from salicylic acid  by coupling 
with the corresponding  2H-azirin-3-amine (Scheme 10).5,19   
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Compound 30 was subjected to the DAC conditions. The starting material disappeared 
quickly (TLC), but even after 35 min the only product formed was the corresponding 
oxazolone 31. After its isolation, further exposure to the same reaction conditions did not 
propagate the reaction further, and the oxazolone 31 was recovered. The stability of the 
oxazolone is in this case extremely high, and apparently a ring enlargement reaction is 
sterically disfavored.  
 
Crystals of 31 suitable for X-ray crystal structure determination were grown from a 
mixture of deuterochloroform and dichloromethane by slow evaporation of the solvent.  
The five membered heterocycle is planar and the phenyl residue is almost coplanar with 
the ring.  The hydroxy group forms an intramolecular hydrogen bond with the imine N-
atom. The interaction can be described by the graph set motif24 of S(6) (for 
crystallographic details see exper. part). 
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Scheme 11 
 
Next, the aromatic ring in 30 was replaced by a cycloaliphatic one. The preparation of the 
precursors 33a,b was achieved in three steps according to Scheme 11. The cyclization 
under the standard conditions led to a mixture of two products, the oxazolone 34 and the 
dehydrated amide 35, but no cyclodepsipeptide could be detected. 
 
3. Computer Modeling 
 
As we were searching for an explanation for the preferred cyclodimerization process of 
diamides of type 1, we carried out some simple quantum mechanical calculations. 
Especially surprising was the discrepancy  with the lower homologue 36, which under the 
DAC conditions gave the cyclic monomer 39 exclusively. Assuming that the reaction 
proceeds indeed via the oxazolone intermediates (37 and 40, respectively), we compared 
the energies of the corresponding monomeric and dimeric ring structures, both in the 
cases of α-hydroxy acids and β-hydroxy acids (Schemes 12 and 13). 
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AM1 calculations30 with Ampac v.6.5.531 revealed that the transition state required to 
achieve a nucleophilic attack of the oxazolone hydroxy group on the carbonyl C-atom is 
more favorable in the case of 40 than in 37, which is to be expected, having in mind the 
length of the alkyl chain to which the OH group is bound.  Nevertheless, under the DAC 
conditions, 36 gives 39, whereas 1 undergoes the twinning process. 
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Scheme 13 
Direct comparison of the heats of formation (∆H) of 38 and 39, as well as those of  3 and 
2, reveals that in the first case (Scheme 12) the formation of the dimer 38 is energetically 
 18 
more unfavorable than the formation of the monomer 39 (2E39 < E38 ). In the second case 
(Scheme 12), formation of the dimer 3 is energetically more favorable than the formation 
of the monomer (2E2 > E3), which suggests that the cause for the different products 
formed is thermodynamic. This crude modeling helps to understand why the dimers of 
type 3 could be the main products of the direct amide cyclization of 1, but it does not 
explain why they are the only products formed. An equilibrium between the monomeric 
and dimeric forms under the strongly acidic conditions of the DAC is to be expected in 
both cases (between 2 and 3 on the one hand and between 39 and 38 on the other). This 
equilibrium might be shifted almost completely in one direction in the case of 3 and in 
the other in the case of 39. 
 
4. Conclusions 
 
Upon investigating the reasons for the cyclodimerization of β-hydroxy acid amides of 
type 1 under various conditions, we were able to isolate five different 14-membered 
cyclodimers of type 3. Although other coupling methods also gave moderate results, the 
best yields were obtained via the ‘direct amide cyclization’ (DAC), reaching 88% for the 
cyclodimer 10. It is worth mentioning that in all cases, when starting with racemic 
material, only the trans-substituted cyclodepsipeptides were isolated.  
 
The cyclodimerization is most probably a result of the greater thermodynamic stability of 
the 14-membered ring compared with the 7-membered one. Another factor which might 
contribute to the cyclodimerization, as suggested in the literature, is H-bond formation, 
which would be more pronounced in the 14-membered ring, although the structures of all 
cyclodepsipeptides which were characterized by X-ray crystallography showed no 
evidence of intramolecular H-bonding. 
 
Molecular modeling using simple AM1 calculations shows in the case of 1 that the 
formation of the dimeric depsipeptide is indeed thermodynamically favored over the 
formation of the monomer, but it does not explain why the 14-membered ring is the only 
product formed. A mixture of the monomeric and dimeric forms is to be expected. Thus, 
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the reason for the exclusive cyclodimerization of compounds of type 1 remains unclear 
and further investigation in this area is needed. 
 
Variation in the substitution pattern of the starting compounds showed that mono-
substitution in the amino acid moiety does not prevent twinning (13, 15 and 16 yielded 
trans-14, although not via DAC). Using I2 mediated lactonization allowed for the 
selective synthesis of both (S,S)-14 (starting with (S)-16) and trans-14 (starting with rac-
16). If, on the other hand, the hydroxy acid moiety is monosubstituted (as in 18, 19, 27), 
although the formation of the intermediate 1,3-oxazol-5(4H)-one  has been monitored by 
IR, dehydration occurs and no cyclic products are formed. Therefore, the synthesis of β-
hydroxy acid containing cyclic depsipeptides via DAC is useful only if the starting 
amides contain α,α-disubstituted acids. 
 
4. Experimental Part 
 
4.1.General.  
 
Thin-layer chromatography (TLC): Merck TLC aluminium sheets, silica gel 60 F254. 
Prep. TLC: Merck PLC plates (glass), silica gel 60 F254, 2 mm and 40-63 µm. Flash 
chromatography (CC): Uetikon-Chemie ‘Chromatographiegel’ C-560. Mp: Büchi 540 
apparatus, uncorrected. IR Spectra: Perkin-Elmer Spectrum one spectrometer; in KBr,  
unless otherwise stated, absorption bands in cm-1. 1H NMR (300 MHz) and 13C NMR 
(75.5 MHz) spectra: Bruker ARX-300 or Bruker DRX-600  instrument; 1H NMR (600 
MHz) and 13C NMR (150 MHz); in CDCl3  at 300 K; TMS as internal standard, unless 
otherwise stated; δ in ppm, coupling constants J in Hz.  Mass spectrometry (MS): 
Finnigan MAT-90 for electron impact ionization (EI), Finnigan SSQ-700 for chemical 
ionization (CI, with NH3) and electrospray ionization (ESI, in MeOH + NaI), unless 
otherwise stated. 
2,2,N,N-Tetramethyl-2H-azirin-3-amine, 2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine, 2-
benzyl-2,N-dimethyl-N-phenyl-2H-azirin-3-amine and N,N-dimethyl-1-
azaspiro[2.4]hept-1-en-2-amine  were prepared according to standard procedures (Refs. 5 
and 7 and refs. cited therein). 3-Hydroxy-2-benzylpropanoic acid was prepared by the 
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method of Monteil et al.28 and methyltropic acid from hydroptropic aldehyde by 
hydroxymethylation, followed by oxidation, according to Geffken.27 Hydroxy acids 32 
were synthesized by the method of Seebach et al.32 All other products used were 
commercially available. 
 
General procedure 1 (GP1).  
To a solution of a hydroxy acid (2-6 mmol) in  dry THF (5-20 mL), 1.05 equiv of the 
corresponding 2H-azirin-3-amine were added dropwise. The mixture was stirred at rt for 
12-36 h, the solvent evaporated and the remaining solid purified by column 
chromatography (CC) over silica gel and dried in h.v. 
 
General procedure 2 (GP2). 
According to GP1, the reaction was stirred overnight, the solvent evaporated, the solid 
residue washed with Et2O and recrystallized from AcOEt. 
 
General procedure 3 (GP3). 
To a solution of a hydroxy acid (3 mmol) in dry THF (10 mL) was added the 
corresponding phenylalanine ester hydrochloride (3.0 mmol) and 3-
(diethoxyphosphoryloxy)-1,2,3-benzotriazine-4(3H)-one (DEPBT, 916 mg, 98%, 3.0 
mmol). To the cooled mixture were added dropwise 12 mmol (1.21 g) Et3N. The mixture 
was stirred at rt overnight, the solvent was partially evaporated, AcOEt was added and 
the solution was washed with 5% aq KHSO4 and with saturated aq NaHCO3 solutions. 
The combined organic fractions were dried over MgSO4, evaporated, purified by CC, and 
dried in h.v. 
 
General Procedure 4 (GP4). 
To a solution of an ester (2.0 mmol) in 10 mL EtOH was added LiOH.H2O (336 mg, 8 
mmol). The reaction was stirred overnight at rt, acidified with 6N HCl, the organic 
solvent was evaporated in vacuo  and the residue extracted with AcOEt. The crude acids 
were used in the next reaction step without further purification. 
 
General procedure 5 (GP5). 
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A suspension of an amide (1 mmol) in dry toluene (50 mL) was heated to 100 oC, and dry 
HCl gas was bubbled through the suspension for 5-15 min. Then, the mixture was 
allowed to cool to rt while bubbling N2 through it (ca. 20 min). The solvent was 
evaporated, the white residue was washed with 3 × 15 mL of CH2Cl2 and dried in h.v. 
 
General procedure 6 (GP6). 
According to GP5, after bubbling N2 through the reaction mixture (ca. 20 min) the 
solvent was evaporated, and the residue purified by CC. 
 
General procedure 7 (GP7). 
To a solution of 13 or 15 (1 mmol) in dry toluene (5 mL), NaH (40 mg of a 60% 
suspension in mineral oil, 1 mmol) was added slowly at 0 oC and under constant stirring 
(N2-atmosphere). After 6 h at 80 oC, the mixture was acidified with 0.1N HCl (~5 mL) to 
pH 5 and extracted with CH2Cl2 . The combined organic fractions were dried (MgSO4) 
and evaporated i.v. The crystalline residue was purified by CC (CH2Cl2/acetone 200:1) 
and dried in h.v. 
 
General procedure 8 (GP8). 
To a solution of a hydroxy acid  (1 mmol )  in acetonitrile (5 mL), I2 (25 mg, 0.1 mmol ) 
was added. After 2 d under reflux, the mixture was cooled and the solvent evaporated. 
After addition of 20 mL of AcOEt and  washing with aq Na2S2O3, the combined organic 
fractions were dried (MgSO4) and evaporated i.v. The crystalline residue was purified by 
CC. 
 
General Procedure 9 (GP9). 
A suspension of an amide (1 mmol) in a toluene/20% ethanol solution (60 mL) was 
heated to 100 oC, and dry HCl gas was bubbled through the suspension for 10 min. Then, 
the mixture was allowed to cool to rt while bubbling N2 through it (ca. 20 min). The 
solvent was evaporated and the oily residue was purified by CC . 
 
General Procedure 10 (GP10). 
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A suspension of an amide (0.5 mmol) in dry toluene (25 mL) was heated to 100 oC, and 
dry HCl gas was bubbled through the suspension for 10 min. Then, the mixture was 
allowed to cool to rt while bubbling N2 through it (ca. 20 min). The solvent was removed 
i.v. and MeOH (15 mL) was added to the residue and stirred at rt for 1 h in the presence 
of 500 mg SiO2. The silicagel was filtered, the solvent was evaporated and the oily 
residue was purified by CC. 
 
4.2. Preparation of 3-Hydroxy-2-methylpropanoic acid. To a solution of methyl 
(R)-3-hydroxy-2-methylpropanoate (1.0 g, 8.38 mmol) in THF/water 75:10 (10 mL) 
LiOH (1.55g, 33.5 mmol) was added at 0 oC. The mixture was stirred overnight, the 
organic solvent evaporated, the residue acidified with 6N HCl to pH 1 and extracted with 
AcOEt. The colorless oil was used in the next reaction without further purification. Yield: 
768 mg (88%). Spectroscopic data in accordance with previously published data.33 The 
optical purity has not been determined. 1H NMR((D6)-DMSO): 1.04 (d, J = 5.9 Hz, CH3); 
2.31-2.38 (m, CH); 3.38-3.44, 3.52-3.61 (2m, CH2); 4.62 (br s, OH); 11.95 (br s COOH). 
 
4.3. Coupling of β-hydroxy acids with 2H-azirin-3-amines  
 
4.3.1. 3-Hydroxy-2,2-dimethyl-N-[1-(N,N-
dimethylcarbamoyl)cyclopentyl]propanamide (9). According to GP1, 3-hydroxy-2,2-
dimethylpropanoic acid (806 mg, 6.84 mmol) in dry THF (10 mL),  N,N-dimethyl-1-
azaspiro[2.4]hept-1-en-2-amine (1.037 g, 7.52 mmol), 18 h, CC (SiO2, acetone/CH2Cl2 
1:20). Yield: 1.330 g (76%) of 9. White solid. Mp 180.6-181.9 oC (AcOEt). IR: 3397vs, 
3279s, 2960s, 2873m, 1644vs, 1542vs, 1469m, 1393s, 1309m, 1257m, 1212w, 1164m, 
1119w, 1061s, 1011w, 983w, 911w, 817w, 669m. 1H NMR ((D6)-DMSO): 1.14 (s, 
Me2C); 1.71 (m, 2CH2); 1.81-2.00, 2.28-2.48 (2m, 2CH2); 2.99 (s, Me2N); 3.56 (br s, 
OH); 4.46 (s, CH2O); 7.42 (br s, NH). 13C NMR ((D6)-DMSO): 22.8 (q, Me2C); 24.2 (t, 
CH2); 37.2 (t, CH2); 37.7 (q, Me2N); 42.8, 66.2 (2s, 2C); 69.1 (t, CH2O); 172.7, 176.9 (2s, 
2CO). CI-MS: 257 (21, [M+H]+), 212.3 (100, [M-NMe2]+). Anal. calcd for C13H24N2O3 
(256.35): C 60.91, H 9.44, N 10.93; found: C 60.24, H 9.50, N 10.76. 
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4.3.2. 3-Hydroxy-2,2-dimethyl-N-[1-methyl-1-(N,N-dimethylcarbamoyl)-2-
phenylethyl]propanamide (11a). According to GP1, 3-hydroxy-2,2-dimethylpropanoic 
acid (436 mg, 2.00 mmol) in dry THF (5 mL), 2-benzyl-2,N,N-trimethyl-2H-azirin-3-
amine (395 mg, 2.1 mmol), 24 h, CC (SiO2, acetone/CH2Cl2 1:20). Yield:  538 mg (88%) 
of 11a. White powder. Mp 92.6-94.9 oC. 1H NMR ((D6)DMSO): 1.05 (s, Me2C); 1.29 (s, 
Me); 3.09 (s, Me2N); 3.13-3.38 (m, PhCH2); 3.54 (s, CH2O); 4.77 (br s, OH); 6.92 (br s, 
NH); 7.06-7.36 (m, Ph). 13C NMR ((D6)DMSO): 22.4 (q, Me2C); 24.8 (q, Me); 37.3 (q, 
MeN); 41.0 (s, Me2C); 43.8 (t, PhCH2); 70.1 (t, CH2O); 128.3, 128.8, 129.4 (3d, 5 arom. 
CH); 136.1 (s, arom. C); 173.1, 175.2 (2s, 2 CO). CI-MS: 307 (100, [M+H]+), 262 (25, 
[M-NMe2]+). 
Recrystallization from DMSO/diethyl ether yielded crystals of 11a, suitable for an X-ray 
crystal structure determination. 
 
4.3.3. 3-Hydroxy-2,2-dimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)-2-
phenylethyl]propanamide (11b). According to GP1, 3-hydroxy-2,2-dimethylpropanoic 
acid (436 mg, 2.00 mmol) in dry THF (5 mL), 2-benzyl-2,N-dimethyl-N-phenyl-2H-
azirin-3-amine (525 mg, 2.1 mmol), 28 h, CC (SiO2, acetone/CH2Cl2 1:30). Yield: 618 
mg (84%) of 11b. White powder. Mp 62.0-64.2 oC. IR: 3385vs, 3291vs, 3060m, 2941vs, 
1701vs, 1634vs, 1591s, 1454s, 1386s, 1312s, 1238s, 1193m, 1165m, 1111m, 1053s, 
886m, 908w, 834w, 772s, 705s. 1H NMR: 0.98, 1.08 (2s, Me2C); 1.33 (s, Me); 3.29 (s, 
MeN); 3.41 (m, PhCH2); 3.54 (s, CH2O); 3.77 (br s, OH); 6.89 (br s, NH); 7.12-4.10 (m, 
2Ph). 13C NMR: 22.1 (q, Me2C); 24.1 (q, Me); 41.8 (q, MeN); 43.4 (s, Me2C); 43.7 (t, 
PhCH2); 70.4 (t, CH2O); 127.1, 128.3, 128.8, 129.5, 130.1 (5d, 10 arom. CH); 136.1, 
144.2 (2s, 2arom. C); 173.0, 177.1 (2s, 2 CO). CI-MS: 369 (30, [M+H]+), 262 (100, [M-
N(Me)Ph]+), 234.2 (20), 160.1 (18), 134.1(36), 107.1 (26). Anal. calcd for C22H28N2O3  
(368.48): C 71.71, H 7.66, N 7.60; found: C 71.79, H 7.82, N 7.07. 
 
4.3.4. 3-Hydroxy-2-phenyl-N-[1-methyl-1-(N,N-
dimethylcarbamoyl)ethyl]propanamide (18a). According to GP2, 3-hydroxy-2-
phenylpropanoic acid (tropic acid, 332 mg, 2.00 mmol) in dry THF (5 mL), 2,2,N,N-
tetramethyl-2H-azirin-3-amine (249 mg, 2.1 mmol), 8 h. Yield: 440 mg (79%) of 18a. 
White powder. Mp 160.8-161.3 oC (AcOEt). IR: 3421m, 3296s, 3060m, 2936m, 1651vs, 
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1619vs, 1540s, 1491m, 1454w, 1396s, 1271m, 1219m, 1123s, 1068m, 1051m, 913w, 
750m, 702m. 1H NMR: 1.88, 1.94 (2s, Me2C); 3.28 (s, Me2N); 3.87-4.12 (m, CH2); 4.42 
(br t, J = 6.8Hz, CH); 6.98 (s, NH); 7.50-7.62 (m, Ph). 13C NMR: 24.3, 24. 5 (2q, Me2C); 
38.0 (q, Me2N); 56.9 (s, Me2C); 54.7 (d, CH); 64.9 (t, CH2O); 127.7, 128.2, 129.0 (3d, 5 
arom. CH); 136.7 (s, arom. C); 171.9, 172.6 (2s, 2CO). 1H NMR ((D6)DMSO): 1.38, 1.32 
(2s, Me2C);  2.71 (s, Me2N); 3.42-3.58, 3.60-3.69, 3.87-3.94 (3m, CH, CH2); 4.78 (t, 
OH); 7.22-7.36 (m, Ph); 8.31 (s, NH). 13C NMR ((D6)DMSO): 25.5, 25.8 (2q, Me2C); 
37.0 (q, Me2N); 53.9 (s, Me2C); 55.4 (d, CH); 63.2 (t, CH2O); 126.6, 127.7, 128.0 (3d, 5 
arom. CH); 138.1 (s, arom. C); 170.2, 171.7 (2s, 2CO). CI-MS: 279 (80, [M+H]+), 234 
(100, [M-NMe2]+), 206 (22), 157 (18), 104 (8). 
 
4.3.5. 3-Hydroxy-2-phenyl-N-[1-methyl-1-(N-methyl-N-
phenylcarbamoyl)ethyl]propanamide (18b). According to GP2, 3-hydroxy-2-
phenylpropanoic acid (tropic acid, 332 mg, 2.00 mmol) in dry THF (5 mL), 2,2,N-
trimethyl-N-phenyl-2H-azirin-3-amine (365 mg, 2.1 mmol), 9 h. Yield: 578 mg (85%) of 
18b. White powder. Mp 128.6-129.9 oC (AcOEt). IR: 3298s, 3274s, 3055m, 2940m, 
1673vs, 16124vs, 1545s, 1488m, 1462w, 1394s, 1270m, 1124s, 1099s, 1060m, 913m, 
745m. 1H NMR: 1.76, 1.89 (2s, Me2C); 3.31 (s, MeN); 3.91-4.19 (m, CH2); 4.36-4.42 (m, 
CH); 7.05 (s, NH); 7.41-7.55, 7.60-7.87 (2m, 2Ph). 13C NMR: 24.6, 24. 8 (2q, Me2C); 
41.1 (q, MeN); 57.4 (s, Me2C); 55.0 (d, CH); 67.3 (t, CH2O); 127.6, 127.7, 128.2, 128.5, 
128.8, 129.1 (6d, 10 arom. CH); 136.7, 143.8 (2s, 2arom. C); 173.1, 173.9 (2s, 2CO). 
ESI-MS:  363 (100, [M+Na]+). 
 
4.3.6. 3-Hydroxy-2-methyl-2-phenyl-N-[1-methyl-(N,N-
dimethylcarbamoyl)ethyl]propanamide  (21a). According to GP1,  3-hydroxy-2-
methyl-2-phenylpropanoic acid  (360 mg, 2.00 mmol) in dry THF (5 mL),  2,2,N,N-
tetramethyl-2H-azirin-3-amine (249 mg, 2.1 mmol), 36 h, CC (SiO2, acetone/CH2Cl2 
1:10). Yield: 455 mg (78%) of 21a. Colorless crystals. Mp 147.6-148.4 oC (toluene). IR: 
3533s, 3280vs, 3054s, 2928vs, 1708vs, 1622vs, 1526vs, 1394s, 1264s, 1208s, 1118s, 
1050m, 976m, 900w, 770m, 751m, 802m. 1H NMR: 1.50 (s, Me2C); 1.61 (s, Me), 3.00 (s, 
Me2N); 3.55-3.70, 4.05-4.19 (2m, CH2O); 4.45 (br s, OH); 7.18-7.41 (m, Ph, NH). 13C-
NMR: 21.4 (q, Me2C); 25.0 (q, Me); 37.7 (q, Me2N); 51.5, 56.4 (2s, 2Me2C); 68.7 (t, 
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CH2O); 126.5, 126.9, 128.3 (3d, 5 arom. CH); 141.5 (s, arom. C); 172.6, 175.3 (2s, 2CO). 
CI-MS: 293 (88, [M+H]+), 248 (100, [M-NMe2]+), 113 (28). Anal. calcd for C16H24N2O3 
(292.38): C 65.73, H 8.27, N 9.58; found: C 65.69, H 8.40, N 9.59. 
 
4.3.7. 3-Hydroxy-2-methyl-2-phenyl-N-[1-methyl-1-(N-methyl-N-
phenylcarbamoyl)ethyl]propanamide (21b). According to GP1,  3-hydroxy-2-methyl-
2-phenylpropanoic acid  (360 mg, 2.00 mmol) in dry THF (5 mL) 2-benzyl-2,N-
dimethyl-N-phenyl-2H-azirin-3-amine (365 mg, 2.1 mmol), 28 h, CC (SiO2, 
acetone/CH2Cl2 1:20). Yield: 608 mg (86%) of 21b. White solid. Mp 132.1-133.0 oC. IR: 
3451s, 3282vs, 3057m, 2992s, 1709s, 1635vs, 1592s, 1445s, 1395s, 1262m, 1157m, 
1123m, 1092s, 1026s, 921m. 1H NMR: 1.30, 1.38 (2s, Me2C); 1.48 (s, Me), 3.22 (s, 
MeN); 3.55-3.61, 4.00-4.10 (2m, CH2O); 4.63 (br s, OH); 6.61 (br s, NH); 7.18-7.41 (m, 
2Ph). 13C NMR: 21.8 (q, Me2C); 25.7 (q, Me); 41.5 (q, MeN); 52.3, 58.8 (2s, 2Me2C); 
69.2 (t, CH2O); 126.3, 126.6, 126.9, 127.1, 127.2, 128.1, 128.3, 128.4, 128.6,  129.4 (10d, 
10 arom. CH); 141.6, 144.2 (2s, 2arom. C); 173.7, 176.0 (2s, 2CO). ESI-MS: 731 (48, 
[2M+Na]+), 377 (100, [M+Na]+), 248 (16). 
 
4.3.8. 3-Hydroxy-2-benzyl-N-[1-methyl-1-(N-methyl-N-
phenylcarbamoyl)ethyl]propanamide (22). According to GP2, 3-hydroxy-2-
benzylpropanoic acid  (360 mg, 2.00 mmol) in dry THF (5 mL), 2,2,N-trimethyl-N-
phenyl-2H-azirin-3-amine (365 mg, 2.1 mmol), 8 h. Yield: 560 mg (79%) of 22. White 
powder. Mp 162.4-163.9 oC. IR: 3409m, 3277s, 3060w, 2932m, 1630vs, 1592s, 1544s, 
1493s, 1395s, 1254m, 1188w, 1092s, 1070m, 769m, 743m, 703s, 617m. 1H NMR: 1.27, 
1.33 (2s, Me2C); 2.38-2.42, 2.61-2.73, 2.88-3.01 (3m, CH2, CH); 3.27 (s, MeN); 3.66-
3.73 (m, OH); 6.18 (br s, NH); 7.11-7.41 (m, 2Ph). 13C NMR:  26.2, 27. 0 (2q, Me2C); 
34.3 (t, CH2); 41.5 (q, MeN); 50.8 (d, CH); 59.0 (s, Me2C); 63.6 (t, CH2O); 126.3, 128.2, 
128.3, 128.5, 129.0, 129.4 (6d, 10 arom. CH); 139.3, 144.4 (2s, 2arom. C ); 173.8, 174.0 
(2s, 2CO). ESI-MS: 377 (100, [M+Na]+). Anal. calcd for C16H24N2O3 (354.45): C 65.73, 
H 8.27, N 9.58; found: C 60.24, H 9.50, N 10.76. 
 
4.3.9. 3-Hydroxy-2-methyl-N-[1-methyl-1-(N,N-
dimethylcarbamoyl)ethyl]propanamide (23). According to GP1, 3-hydroxy-2-
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methylpropanoic acid  (416 mg, 4.00 mmol) in dry THF (5 mL),  2,2,N,N-tetramethyl-
2H-azirin-3-amine (498 mg, 4.2 mmol), 38 h, CC (SiO2, acetone/CH2Cl2 1:20). Yield: 
790mg (83%) of 23. Colorless crystals. Mp 118.7-120.0 oC. IR: 3418s, 1619vs, 1540s, 
1397s, 1279m, 1226s, 1124s, 1077m, 1036m. 1H NMR: 1.09 (d, J = 6.1 Hz, Me); 1.58 (s, 
Me2C); 2.59 (m, CH); 3.06 (s, Me2N); 3.63 (d, CH2); 4.21 (br s, OH); 7.70 (s, NH). 13C 
NMR: 13.7 (q, Me); 25.5, 25. 6 (2q, Me2C); 37.9 (q, MeN); 56.3 (s, Me2C); 42.3 (d, CH); 
64.8 (t, CH2O); 173.0, 174.9 (2s, 2CO). ESI-MS: 455 (20, [2M+Na]+), 239 (100, 
[M+Na]+). Anal. calcd for C10H20N2O3 (216.28): C 55.53, H 9.32, N 12.95; found: C 
55.74, H 9.71, N 13.12. 
 
4.3.10. 2-Hydroxy-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]benzamide 
(30). According to GP1,  salicylic  acid  (276 mg, 2.00 mmol) in dry THF (5 mL),  2,2,N-
trimethyl-N-phenyl-2H-azirin-3-amine (365 mg, 2.1 mmol), CC (SiO2, acetone/CH2Cl2 
1:20). Yield: 565mg (92%) of 30. Colorless crystals. Mp 146.1-147.8 oC . IR: 3533s, 
3280vs, 3054s, 2928vs, 1708vs, 1622vs, 1526vs, 1394s, 1264s, 1208s, 1118s, 1050m, 
976m, 900w, 770m, 751m, 802m. 1H NMR: 1.43 (s, Me2C); 3.22 (s, MeN); 6.68-6.74 (m, 
1arom. H); 6.76 (br s, NH); 6.92-7.0 (m, 2H arom);7.11-7.28 (m, 4arom. H); 7.31-7.42  
(m, 2arom. H); 12.1 (s, OH). 13C NMR: 26.4 (q, Me2C); 41.4 (q, MeN); 58.4 (s, Me2C); 
119.9 (s, arom. C); 126.6, 126.8, 127.3, 127.9, 128.2, 128.9, 129.3 (7d, 9 arom. CH); 
134.1, 142.2 (2s, 2arom. C); 172.9, 177.5 (2s, 2CO). ESI-MS: 335 (100, [M+Na]+). 
 
4.3.11. (1R,2S)-2-Hydroxy-N-[1-methyl-1-(N-methyl-N-
phenylcarbamoyl)ethyl]cyclopentanecarbonamide (33a) According to GP1, (1R,2S)-
2-hydroxycyclopentanoic acid (32a, 260 mg, 2.00 mmol) in dry THF (5 mL),  2,2,N-
trimethyl-N-phenyl-2H-azirin-3-amine (365 mg, 2.1 mmol), CC (SiO2, acetone/CH2Cl2 
1:10). Yield:  530 mg (86%) of 33a. White powder. Mp 153.4-155.0 oC. IR: 3289s,  
2943s, 1708vs, 1636vs, 1593s, 1494s, 1390s, 1240s, 1092s, 1028m, 919m, 732s. 1H 
NMR: 1.42 (s, Me2C); 1.57-1.68, 1.70-1.77, 1.79-1.96 (3m, 3CH2, CH); 3.27 (s, MeN); 
4.35 (m, CHO);  6.38 (br s, NH); 7.24-7.41 (m, Ph, NH). 13C NMR: 21.9 (t, CH2); 26.1, 
26.4 (2q, Me2C); 26.8, 33.9 (2t, 2CH2); 41.4 (q, MeN); 50.2 (d, CH); 58.6 (s, Me2C); 74.2 
(d, CHO); 128.1, 128.3, 129.4 (3d, 5 arom. CH); 144.2 (s, arom. C); 173.4, 176.1 (2s, 
2CO). ESI-MS: 327 (100, [M+Na]+). 
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4.3.12. (1R,2S)-2-Hydroxy-N-[1-methyl-1-(N-methyl-N-
phenylcarbamoyl)ethyl]cyclohexanecarbonamide (33b). According to GP1, (1R,2S)-2-
hydroxycyclohexanoic acid (32b, 288 mg, 2.00 mmol) in dry THF (5 mL),  2,2,N-
trimethyl-N-phenyl-2H-azirin-3-amine (365 mg, 2.1 mmol), 12 h, CC (SiO2, 
acetone/CH2Cl2 1:10).Yield: 566 mg (89%) of 33b.White powder. Mp 171.2-172.9 oC. 
IR: 3290s, 3020m, 2948s, 1711vs, 1635vs, 1599s, 1491s, 1421m, 1391s, 1239s, 1091s, 
1022m, 919m, 731s. 1H NMR: 1.37, 1.42 (2s, Me2C); 1.43-1.52, 1.62-1.74, 1.77-1.83, 
1.86-1.95 (4m, 4CH2, CH); 3.21 (s,  MeN); 3.97 (m, CHO);  6.41 (br s, NH); 7.22-7.41 
(m, Ph, NH). 13C NMR: 19.2, 24.4, 24.9 (3t, 3CH2); 25.9, 26.1 (2q, Me2C); 31.7 (t, CH2); 
41.4 (q, MeN); 47.9 (d, CH); 59.4 (s, Me2C); 66.7 (d, CHO); 127.9, 128.2, 129.3 (3d, 5 
arom. CH); 142.2 (s, arom. C); 172.1, 177.4 (2s, 2CO). ESI-MS: 341 (100, [M+Na]+). 
 
4.4. Preparation of dipeptide esters 
 
4.4.1. tert-Butyl (S)-2-(3-hydroxy-2,2-dimethylpropanoylamino)-3-phenylpropanoate 
(13). According to GP3, 3-hydroxy-2,2-dimethylpropanoic acid (654 mg, 3 mmol), L-
phenylalanine tert-butyl ester hydrochloride (774 mg, 3.0 mmol), CC (SiO2, 
acetone/CH2Cl2 1:30). Yield: 857 g (89%) of 13. Colorless solid. Mp 82.7-84.1 oC. 
[α]25,D = +44.6 (c = 1, CHCl3). IR: 3265vs, 3006s, 2982vs, 2867s, 1721vs, 1635vs, 
1543vs, 1455s, 1392s, 1315s, 1165vs, 1102m, 963s, 850m. 1H NMR: 1.09 (s, Me2C); 
1.45 (s, Me3C), 3.00-3.17 (m, PhCH2); 3.42-3.51 (m, CH2O); 3.72 (br s, OH); 4.63-4.78 
(m, CH); 6.94 (br s,  NH); 7.13-7.36 (m, Ph). 13C NMR: 22.3 (q, Me2C); 27.8 (q, Me3C); 
37.6 (t, CH2); 43.1 (s, Me2C); 53. (d, CH); 69.9 (t, CH2); 82.3 (s, Me3C); 126.9, 128.3, 
129.3 (3d, 5 arom. CH); 136.1 (s, arom. C); 170.8, 177.1 (2s, 2CO). CI-MS: 322 (88, 
[M+H]+), 266 (100, [M- tBu)]+). Anal. calc. for C18H27NO4 (321.42): C 67.26, H 8.47, N 
4.36; found: C 67.04, H 8.66, N 4.20. 
 
4.4.2. Methyl  (RS)-2-(3-hydroxy-2,2-dimethylpropanoylamino)-3-phenylpropanoate 
(15). According to GP3, 3-hydroxy-2,2-dimethylpropanoic acid (654 mg, 3 mmol), DL-
phenylalanine methyl ester hydrochloride (639 mg, 3.0 mmol), CC (SiO2, 
acetone/CH2Cl2 1:30). Yield: 673 g (80%) of 15. Pale yellow oil. 1H NMR: 1.03 (s, 
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Me2C); 2.98-3.12 (m, PhCH2); 3.36-3.49 (m, CH2O); 3.67 (s, MeO);  4.68-74 (m, CH); 
6.50 (br s,  NH); 7.13-7.38 (m, Ph). 13C NMR: 22.2 (q, Me2C); 37.6 (t, CH2); 43.0 (s, 
Me2C); 52.2 (d, CH); 52.9 (q, MeO); 69.5 (t, CH2); 127.0, 128.4, 129.1 (3d, 5 arom. CH); 
135.8 (s, arom. C); 172.2, 177.3 (2s, 2CO). CI-MS: 280 (100, [M+H]+), 162 (18). Anal. 
calcd for C15H13NO4 (279.34): C 64.50, H 7.58, N 5.01; found: C 64.15, H 7.73, N 4.89. 
 
4.4.3. Methyl  (S)-2-(3-hydroxy-2,2-dimethylpropanoylamino)-3-phenylpropanoate 
(17). According to GP3, 3-hydroxy-2,2-dimethylpropanoic acid (654 mg, 3 mmol), L-
phenylalanine methyl ester hydrochloride (639mg, 3.0 mmol), CC (SiO2, acetone/CH2Cl2 
1:30). Yield: 720 g (86%) of 17. Pale yellow oil. 1H NMR: 1.05 (s, Me2C); 3.00-3.09 (m, 
PhCH2); 3.38-3.48 (m, CH2O); 3.69 (s, MeO);  4.71 (t, J = 6.0 Hz, CH); 6.52 (s, NH); 
7.14-7.36 (m, Ph). 13C NMR: 22.3 (q, Me2C); 37.7 (t, CH2); 43.0 (s, Me2C); 52.1 (d, CH); 
53.0 (q, MeO); 69.6 (t, CH2); 127.0, 128.4, 129.1 (3d, 5 arom. CH); 135.9 (s, arom. C); 
172.3, 177.5 (2s, 2CO). CI-MS: 280 (100, [M+H]+), 162 (18). 
 
4.4.4. tert-Butyl (R,S)-2-(3-Hydroxy-2-phenylpropanoylamino)-3-phenylpropanoate 
(20). According to GP3, tropic acid (498 mg, 3 mmol), L-phenylalanine tert-butyl ester 
hydrochloride (774 mg, 3.0 mmol), CC (SiO2, acetone/CH2Cl2 1:30). Yield: 974 mg 
(88%) of 20. Pale yellow crystals. Mp 117.4-119.1 oC. IR: 3426s, 3290s, 3059m, 1738vs, 
1658vs, 1635s, 1551m, 1454m, 1368s, 1223s, 1154vs, 1059m, 1023m, 845m, 740m, 
701s. 1H NMR ((D6)DMSO): 1.28, 1.31 (2s, Me3C); 2.91-3.10 (m, PhCH2); 3.50-3.62, 
3.69-3.80 (2m, CH2O); 4.00-4.16,  4.60-4.78 (2m, 2CH); 5.81-6.00 (m, OH); 6.73 (d, J = 
3.7 Hz,  NH); 6.93-7.27 (m, 2Ph). 13C NMR: 27.8, 27.9 (2q, Me3C); 37.7 (t, CH2); 53.1, 
53.5, 54.3, 54.4 (4d, 2CH); 64.7, 64.8 (t, CH2O); 81.8 (s, Me3C); 127.7, 128.2, 128.3, 
128.4, 129.0, 129.3 (6d, 10 arom. CH); 136.1, 136.8 (2s, 2arom. C); 171.0, 173.2 (2s, 2 
CO). CI-MS: 370 (85, [M+H]+), 313(100, [M - tBu)]+). 
 
4.5. Saponification of dipeptide amides 
 
4.5.1. (RS)-2-(3-Hydroxy-2,2-dimethylpropanoylamino)-3-phenylpropanoic acid 
(rac-16). According to GP4, from 13 (642 mg, 2.0 mmol). Yield 454 mg (79%) of 13. 
White solid. Mp 91.3-94.9 oC. 1H NMR: 0.99, 1.02 (2s, Me2C); 2.96-3.02, 3.08-3.14 (2m, 
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PhCH2); 3.21-3.41 (m, CH2O);  4.66-4.78 (m, CH); 6.95 (br s, NH); 6.98-7.18 (m, Ph). 
13C NMR: 22.0 (q, Me2C); 37.0 (t, CH2); 43.3 (s, Me2C); 53.1 (d, CH); 69.3 (t, CH2);  
127.0, 128.4, 129.3 (3d, 5 arom. CH); 135.8 (s, arom. C);  174.0, 178.1 (2s, 2CO). ESI-
MS: 288 (100, [M+H]+). 
 
4.5.2. (S)-2-(3-Hydroxy-2,2-dimethylpropanoylamino)-3-phenylpropanoic acid ((S)-
16). According to GP4, from 17 (558 mg, 2.0 mmol). Yield: 442 mg (79%) of (S)-16. 
Colorless oil, [α]25,D = +44.1 (c = 1, CHCl3). IR: 3369vs, 3192s, 2963s, 1723vs, 1643vs, 
1529vs, 1455s, 1394m, 1287m, 1254s, 1179m, 1111w, 1049s, 913w, 699s. 1H NMR: 
0.99, 1.01 (2s, Me2C); 2.88-2.94, 3.02-3.14 (2m, PhCH2); 3.38 (m, CH2O); 4.71-4.83 (m, 
CH); 6.71 (br s, NH); 6.98-7.18 (m, Ph). 13C NMR: 21.1 (q, Me2C); 36.1 (t, CH2); 42.4 (s, 
Me2C); 52.2 (d, CH); 68.5 (t, CH2); 126.1, 127.6, 128.4 (3d, 5 arom. CH); 134.9 (s, arom. 
C);  173.2, 177.2 (2s, 2CO). ESI-MS: 288  (100, [M+Na]+). 
 
4.6. Solvolysis of dipeptide amides under DAC conditions 
 
4.6.1. Ethyl 2-(3-hydroxy-2-phenylpropanoylamino)-2-methylpropanoate (19). 
According to GP9, 18 (278 mg, 1 mmol) in  toluene/EtOH 80/20 (60 mL), CC 
(AcOEt/hexane 1:10). Yield: 209 mg (76%) of 19. Colorless oil. IR: 3237vs, 3068s, 
2980s, 1734vs, 1642vs, 1557s, 1475s, 1383m, 1288s, 1164s, 1070m, 1037s, 872w, 751m, 
699s. 1H NMR: 1.10 (t, J = 6.1 Hz, Me); 1.42 (s, Me2C); 3.50-3.60, 3.63-3.72 (2m, CH2); 
3.91-4.13 (m, CH, CH2); 6.02 (s, OH); 7.11-7.29 (m, Ph, NH). 13C NMR:  13.9 (q, Me); 
24. 5 (q, Me2C); 54.4 (d, CH); 56.6 (s, Me2C); 61.5 (t, CH2); 65.1 (t, CH2O); 127.7, 
128.3, 129.0 (3d, 5 arom. CH); 136.5 (s, arom. C); 172.8, 174.2 (2s, 2CO). ESI-MS: 280 
(100, [M+H]+).  
 
4.6.2. Methyl 2-methyl-2-(2-phenylacryloylamino)propanoate (26). According to 
GP10, 18 (139 mg, 0.5 mmol) in  toluene (30 mL), CC ( AcOEt/hexane 1:10). Yield: 72 
mg (58%) of 26. White crystals. Mp 116.8-117.4 oC. IR: 3328m, 3068m, 2960vs, 2861s, 
1727vs, 1657s, 1533s, 1460s, 1382m, 1276vs, 1139s, 1073s, 944w, 731m. 1H NMR: 1.56 
(s, Me2C); 3.77 (s, MeO); 5.60, 6.10 (2s, H2C=); 6.28 (br s, NH); 7.30-7.42 (m, Ph). 13C 
NMR: 24.6 (q, Me2C); 52.6 (s, MeO); 56.7 (s, Me2C); 121.7 (t, H2C=); 127.9, 128.6, 
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128.9 (3d, 5 arom. CH); 136.8 (s, C=CH2); 144.7 (s, arom. C); 166.6, 174.7 (2s, 2CO). 
CI-MS: 265(6, [M+NH4]+), 249 (14), 248 (100, [M+H]+). 
 
4.6.3. Methyl  2-(2-benzyl-3-hydroxypropanoylamino)-2-methylpropanoate (27). 
According to GP9, 22 (188 mg, 0.5 mmol) in toluene/MeOH 80/20 (30 mL), CC 
(AcOEt/hexane 1:10). Yield: 81 mg (58%) of 22. Colorless oil. 1H NMR: 1.41, 1.44 (2s, 
Me2C); 2.59 (m, CH); 2.82 (m, CH2); 3.51, (br s, OH); 3.71 (m, MeO, CH2); 6.50 (s, 
NH); 7.11-7.31 (m, Ph). 13C NMR: 26.3 (q, Me2C); 35.2 (t, CH2); 48.4 (s, MeO); 51.1 (d, 
CH); 55.1 (s, Me2C); 66.0 (t, CH2); 126.6, 128.4, 128.9 (3d, 5 arom. CH); 138.0 (s, arom. 
C); 170.9, 172.9 (2s, 2CO). CI-MS: 281 (16), 280 (100, [M+H]+). 
 
4.7. Attempted cyclization reactions 
 
4.7.1. Direct Amide Cyclisation 
 
4.7.1.1. 8,8,19,19-Tetramethyl-10,21-dioxa-6,17-diazadispiro[4.6.4.6]docosane-
7,11,18,22-tetraone (10). According to GP5,  9 (256 mg, 1 mmol) in  dry toluene (50 
mL) for 15 min. Yield:  186 mg (88%) of 10. White powder. Mp 344.8-346.4 oC 
(decomp). IR: 3386vs, 3029w, 2989s, 2936s, 1715vs, 1668vs, 1519vs, 1470m, 1268vs, 
1190m, 1126vs, 1012m, 804w, 699s. 1H NMR ((D7)DMF): 1.00 (s, 2Me2C ); 1.46-1.54 
(m, 4CH2); 1.75-1.82, 1.88-1.94 (2m, 4CH2);  3.94 (s, 2CH2O); 7.69 (s, 2NH). 13C NMR 
((D7)DMF): 22.8 (q, 2Me2C ); 24.7, 36.1 (2t, 8CH2);  41.3, 65.2 (2s, Me2C, 2C);  70.8 (t, 
2CH2O); 173.9 174.5 (2s, 4CO). CI-MS: 441 (21), 440 (90, [M+Na]+), 423 (100, 
[M+H]+). Anal. calcd for C22H34N2O6 (422.53): C 62.54, H 8.11, N 6.63; found: C 61.89, 
H 8.07, N 6.56. 
Recrystallization from DMF/toluene/ethyl acetate yielded crystals of 10, suitable for an 
X-ray crystal structure determination. 
 
4.7.1.2. 3,10-Dibenzyl-3,6,6,10,13,13-hexamethyl-1,8-dioxa-4,11-
diazacyclotetradecane-2,5,9,12-tetraone (12). According to GP 5,  11 (368 mg, 1 
mmol) in  dry toluene (50 mL), for 15 min. Yield:  177 mg (34%) of 12. White solid. Mp 
288.1-290.5 oC (decomp). IR: 3520m, 3460vs, 3057w, 2970s, 1744vs, 1660vs, 1527vs, 
 31 
1483s, 1364s, 1260s, 1236m, 1121vs, 1020w, 719m, 701s. 1H NMR : 1.11, 1.25, 1.46 
(3s, 6Me); 3.28-3.38 (m, 2PhCH2); 4.09 (s, 2CH2O); 7.07 (s, 2NH); 7.21-7.31 (m, 10 
arom. H). 13C-NMR: 21.3, 21.8 (2q, 2Me2C); 28.7 (q, 2Me); 39.7 (s, 2Me2C); 41.3 (t,  
2CH2 ); 58.4 (s, 2C); 70.2 (t, 2CH2O); 126.1, 127.3, 129.6 (3d, 10 arom. CH); 135.0 (s, 
2arom. C); 171.7, 173.2 (2s, 4CO). ESI-MS: 545 (100, [M+Na]+). 
Recrystallization from DMF/benzene/CH2Cl2/hexane/i-PrOH yielded crystals of 12, 
suitable for an X-ray crystal structure determination. 
 
4.7.1.3. 3,6,6,10,13,13-Hexamethyl-3,10-diphenyl-1,8-dioxa-4,11-
diazacyclotetradecane-2,5,9,12-tetraone (24). According to GP6,  21a (292 mg, 1 
mmol) in  dry toluene (50 mL), 15 min, (SiO2, acetone/ CH2Cl2 1:60). Yield: 75 mg 
(30%) of 24. White solid. Mp 251.6-253.1 oC (decomp). IR: 3526m, 3435vs, 3023w, 
2987s, 1736vs, 1665vs, 1519vs, 1384s, 1276s, 1142vs, 1081w, 998s, 770m, 699s. 1H 
NMR: 1.30, 1.51, 1.60  (3s, 6Me ); 4.41-4.61 (m, 2CH2O); 7.07 (s, 2NH); 7.28-7.42 (m, 
10 arom. H). 13C-NMR: 22.6, 24.5 (2q, 2Me2C ); 25.7 (q, 2Me); 50.6 (s, 2Me2C);  56.1 (s, 
2C); 70.0 (t, 2CH2O); 126.4, 127.7, 128.9 (3d, 10 arom. CH); 141.0 (s, 2arom. C); 172.9 
173.5 (2s, 4CO). CI-MS: 513 (32), 512 (100, [M+NH4]+), 495  (28, [M+H]+). 
Recrystallization from toluene/MeCN/acetone yielded crystals of 24, suitable for an X-
ray crystal structure determination. 
 
4.7.1.4. Reaction of 22 under DAC conditions. A suspension of 22 (188 mg, 0.5 mmol) 
in  toluene (30 mL) was heated to 100 oC, and dry HCl gas was bubbled through the 
suspension for 20 min (IR monitoring). Then, the mixture was allowed to cool to rt while 
bubbling N2 through it (ca. 20 min), MeOH was added to the solution and stirred at rt for 
1 h. The solvent was evaporated, the oily residue was purified by CC (AcOEt/hexane 
1:10) yielding 27 (13 mg, 9%), 28 (28 mg, 21%) and 29 (36 mg, 30%). 
 
4.7.1.4.1. Methyl 2-(2-benzylacryloylamino)-2-methylpropanoate (28). Colorless oil. 
IR: 3332m, 3069m, 2954vs, 2861s, 1727vs, 1661s, 1537s, 1454s, 1364m, 1282vs, 1241s, 
1144s, 1073s, 1026m, 931w, 731m, 701m. 1H NMR: 1.46, 1.49 (2s, Me2C); 3.61 (s, 
CH2); 3.71 (s, MeO); 5.22, 5.79 (2s, H2C=); 6.32 (br s, NH); 7.14-7.32 (m, Ph). 13C 
NMR: 24.5 (q, Me2C); 38.5 (t, CH2); 52.4 (s, MeO); 56.4 (s, Me2C); 119.6 (t, H2C=); 
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126.4, 128.4, 128.8 (3d, 5 arom. CH); 138.2 (s, arom. C); 144.4 (s, C=CH2); 167.3, 174.8 
(2s, 2CO). CI-MS: 263 (18), 262 (100, [M+H]+). 
 
4.7.1.4.2. 2-Benzyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]acrylamide 
(29). White solid. Mp 119.1-121.6 oC. IR: 3282s, 3060w, 2932m, 1634vs, 1598s, 1541s, 
1481s, 1421m, 1390s, 1254m, 1172w, 1090s, 1079m, 769m, 703s. 1H NMR: 1.41 (s, 
Me2C); 3.20 (s, MeN); 3.46 (s, CH2); 5.10, 5.53 (2s, H2C=); 6.18 (br s, NH); 7.09-7.39 
(m, 2Ph). 13C NMR: 26.1 (q, Me2C); 38.4 (t, CH2); 41.3 (q, MeN); 58.1 (s, Me2C); 120.0 
(t, H2C=); 126.5, 127.8, 128.1, 128.6, 129.0, 129.4 (6d, 10 arom. CH); 138.4, 143.4 (2s, 
2arom. C); 144.4 (s, C=CH2); 166.5, 173.1 (2s, 2CO). CI-MS: 237 (52, [M+H]+), 230 
(100, [M-N(Me)Ph]+), 108 (18). 
 
4.7.1.5. 2-(2-Hydroxyphenyl)-4,4-dimethyl-1,3-oxazol-5(4H)-one (31). According to 
GP6, 30 (156 mg, 0.5 mmol) in  dry toluene (50 mL), 5 min (SiO2, acetone/CH2Cl2 1:40). 
Yield: 73 mg (74%) of 31. Colorless crystals. Mp. 68.2-69.0 oC. IR: 3079m,  2977s, 
1823vs, 1643vs, 1615vs, 1579s, 1478s, 1320vs, 1251s, 1206s,  1090s, 1016s, 915s, 735s. 
1H NMR: 1.55 (s, Me2C); 6.84-7.08, 7.41-7.49, 7.68-7.73 (3m, 4arom. H). 13C NMR: 
24.8 (q, Me2C); 64.5 (s, Me2C); 108.8 (s, arom. C); 117.2, 119.3, 128.2, 134.5 (d, 4 arom. 
CH); 160.0 (s, C=N); 161.8 (s, arom. C); 178.6 (s, CO). CI-MS: 206 (100, [M+NH4]+). 
Recrystallization from CDCl3/CH2Cl2 yielded crystals of 31, suitable for an X-ray crystal 
structure determination. 
 
4.7.1.6. Reaction of 33a under DAC conditions. According to GP6, 33a  (152 mg, 0.5 
mmol) in  dry toluene (50 mL), 6 min, CC (SiO2, acetone/CH2Cl2 1:10). Yield:  51 mg 
(34%) of 35a and 30 mg (28%) of 34a. 
 
4.7.1.6.1. N-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]cyclopent-1-
enecarboxamide (35a). White solid. Mp 109.6-111.1 oC. 1H NMR: 1.53 (s, Me2C); 1.84-
1.95, 2.22-2.26, 2.37-2.44 (3m, 3 CH2); 3.26 (s,  Me2N); 5.81 (m, CH=);  6.43 (br s, NH); 
7.20-7.23, 7.29-7.34 (m, Ph). 13C NMR: 23.4 (t, CH2); 26.6 (q, Me2C); 31.0, 31.1, 32.8 
(3t, 3CH2); 41.3 (q, MeN); 57.7 (s, Me2C); 117.9 (s, C=); 127.6, 127.8, 129.1 (d, 5 arom. 
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CH); 139.4 (d, CH=); 144.5 (s, arom. C); 169.0, 173.1 (2s, 2CO). ESI-MS: 202 (100, 
[M+Na]+). 
 
4.7.1.6.2. 2-(2-Hydroxycyclopentyl)-4,4-dimethyl-1,3-oxazol-5(4H)-one (34a). White 
solid. M.p. 98.0-102.1 oC (decomp). IR: 3080w, 2980m, 1822vs, 1642s, 1597s, 1472m, 
1382w, 1216m, 1095s, 1018m, 916s. 1H NMR: 1.56 (s, Me2C); 1.54-1.75, 1.79-1.98 (2m, 
3 CH2, CH); 4.41 (m, CHO). 13C NMR: 22.4 (t, CH2); 25.4, 25.8 (2q, Me2C); 27.8, 31.1 
(3t, 3CH2); 54.4 (d, CH); 62.3 (s, Me2C); 76.1 (d, CHO); 162.5 (s, C=N); 173.1 (s, CO). 
CI-MS: 229 (100, [M+NH4]+). 
 
4.7.1.7. Reaction of 33b under DAC conditions. According to GP6, 33b (158 mg, 0.5 
mmol) in  dry toluene (50 mL), 6 min, CC (SiO2, acetone/CH2Cl2 1:10). Yield:  51 mg 
(34%) of 35b and 31 mg (31%) of 34b. 
 
4.7.1.7.1. N-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]cyclohex-1-
enecarboxamide (35b). White crystals. Mp 112.1-113.8 oC. 1H NMR: 1.46 (s, Me2C); 
1.52-1.62, 1.84-1.96, 2.01-2.14 (3m, 4CH2); 3.26 (s, MeN); 5.85 (m, CH=); 6.53 (br s, 
NH); 7.18-7.20, 7.30-7.36 (m, Ph). 13C NMR: 21.4, 21.9, 23.8, 25.2 (4t, 4CH2); 26.6 (q, 
Me2C); 41.3 (q, MeN); 57.6 (s, Me2C); 117.1 (s, CH=); 127.7, 129.1, 129.3 (3d, 5arom. 
CH); 133.9 (d, CH=); 144.5 (s, arom. C); 169.6, 173.2 (2s, 2CO). ESI-MS: 323 (100, 
[M+Na]+). 
 
4.7.1.7.2. 2-(2-Hydroxycyclohexyl)-4,4-dimethyl-1,3-oxazol-5(4H)-one (34b). White 
solid. Mp 101.1-105.2 oC (decomp). IR: 3288w, 3017m, 29619m, 1824vs, 1638s, 1595s, 
1490m, 1421m, 1380m, 1092s, 917s. 1H NMR: 1.39, 1.43 (2s, Me2C); 1.44-1.56, 1.64-
1.89, 1.90-1.98 (3m, 4CH2); 4.01 (m, CHO). 13C NMR: 19.8, 24.9, 26.6 (3t, 3CH2); 26.0, 
26.1 (q, Me2C); 31.9 (t, CH2); 49.0 (d, CH); 64.0 (s, Me2C); 66.9 (d, CHO); 163.1 (s, 
C=N);  176.8 (s, CO). CI-MS: 215 (100, [M+NH4]+). 
 
 
 
 
 34 
4.7.2. Other cyclizations 
 
4.7.2.1. trans-3,10-Dibenzyl-6,6,13,13-tetramethyl-1,8-dioxa-4,11-
diazacyclotetradecane-2,5,9,12-tetraone (trans-14). According to GP7, 15 (321 mg, 1 
mmol) or 13  (279 mg, 1 mmol). Yield of  trans-14:  108 mg (44%) (from 13) and 60 mg 
(24%) (from 15), respectively. Colorless crystals. M.p. 232.9-234.6 oC (decomp). [α]25,D 
= 0 (c = 1, CHCl3). IR: 3374vs, 3024w, 2966m, 1732vs, 1645vs, 1531s, 1366m, 1282s, 
1179s, 1108w, 1001m, 751m, 700m. 1H NMR: 0.90, 0.98 (2s, Me2C); 3.06 (d, J = 5.8 Hz, 
CH2); 3.91-3.96 (m, CH2); 4.80-4.84 (m, CH); 5.89 (d, J = 3.9 Hz, NH); 6.97-6.99 (m, 
6arom. H); 7.10-7.25 (m, 4arom. H). 13C NMR: 21.6, 22.7 (2q, Me2C); 37.6 (t, 2CH2); 
42.2 (s, 2C); 52.5 (d, 2CH); 70.9 (t, 2CH2O); 127.2, 128.6, 129.3 (3d, 10 arom. CH); 
135.7 (s, 2arom. C); 170.0, 174.0 (2s, 4CO). ESI-MS: 517 (100, [M+Na]+), 444 (11). CI-
MS: 513 (30), 512 (100, [M+NH4]+), 496 (12), 495 (30, [M+H]+). Anal. calcd for 
C28H34N2O6 (494.59): C 68.00, H 6.93, N 5.66; found: C 67.69, H 7.08, N 5.48. 
Recrystallization from i-PrOH/CH2Cl2/hexane yielded crystals of trans-14, suitable for 
an X-ray crystal structure determination. 
 
According to GP8, rac-16  (287 mg, 1 mmol), CC (CH2Cl2/acetone 200:1) yielded  trans-
14 as white crystals in 25% yield (62 mg). [α]25,D = 0 (c = 1, CHCl3). 
 
4.7.2.2. cis-(S,S)-3,10-Dibenzyl-6,6,13,13-tetramethyl-1,8-dioxa-4,11-diaza-
cyclotetradecane-2,5,9,12-tetraone ((S,S)-14). According to GP8, (S)-16 (1 mmol, 287 
mg), CC (CH2Cl2/acetone 200:1). Yield 54 mg (22%) of (S,S)-14b. Mp 212.1-214.4 oC 
(decomp). [α]25,D = -26.3 (c = 1, CHCl3). 
1H NMR: 0.88, 1.08 (2s, 2Me2C); 3.13 (s, 
2CH2O); 3.91-4.04, 4.11-4.22 (2m, 2CH2); 4.83-5.00 (m, 2CH); 5.83 (br s, 2NH); 7.03-
7.14, 7.28-7.42 (2m, 2Ph). 13C-NMR: 21.5, 22.7 (2q, 2Me2C); 37.6 (t, 2CH2); 42.1 (s, 
2C); 53.3 (d, 2CH); 71.0 (t, 2CH2); 127.3, 128.7, 129.4 (3d, 10 arom. CH); 136.1 (s, 
2arom. C); 169.7, 174.3 (2s, 4CO). ESI-MS: 517 (100, [M+Na]+), 444 (11). 
Recrystallization from CH2Cl2/sec-BuOH yielded crystals of (S,S)-14, suitable for an X-
ray crystal structure determination. 
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4.8. X-Ray crystal structure determination of 10, 11a, 12, trans-14, (S,S)-14, 24 
and 31 
 
All measurements were made on a Nonius KappaCCD area-detector diffractometer34 
using graphite-monochromated MoKα radiation (λ 0.71073 Å) and an Oxford 
Cryosystems Cryostream 700 cooler. The data collection and refinement parameters are 
given below35 and views of the molecules are shown in Figures 1-3. Data reduction was 
performed with HKL Denzo and Scalepack.36 The intensities were corrected for Lorentz 
and polarization effects, but not for absorption. Equivalent reflections were merged. Each 
structure was solved by direct methods using SIR92,37 which revealed the positions of all 
non-hydrogen atoms. 
In the case of 10, 12, trans-14 and 24, the molecule sits about a crystallographic centre of 
inversion.  
In the case of (S,S)-14, there are two symmetry-independent molecules in the asymmetric 
unit.  The atomic coordinates of the two molecules were tested carefully for a relationship 
from a higher symmetry space group using the program PLATON,38 but none could be 
found.  The crystal is merohedrally twinned.  Successful refinement of the structure was 
achieved using the twin operator [1 0 0 / 0 -1 0 / 0 0 -1] and the major twin domain has a 
volume fraction of 0.640(1). 
The non-hydrogen atoms were refined anisotropically.  Any amide or hydroxy H-atoms 
in the structures were placed in the positions indicated by a difference electron density 
map and their positions were allowed to refine together with inividual isotropic 
displacement parameters.  All remaining H-atoms were placed in geometrically 
calculated positions and refined using a riding model where each H-atom was assigned a 
fixed isotropic displacement parameter with a value equal to 1.2Ueq of its parent C-atom 
(1.5Ueq for the methyl groups). Except for 11a, the refinement of each structure was 
carried out on F2 by using full-matrix least-squares procedures, which minimised the 
function Σw(Fo2 – Fc2)2. The refinement of the structure ob 11a was carried out on F by 
minimizing the corresponding function based of F. Corrections for secondary extinction 
were applied.  
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Neutral atom scattering factors for non-hydrogen atoms were taken from Ref. 39, and the 
scattering factors for H-atoms were taken from Ref. 40. Anomalous dispersion effects 
were included in Fc,41 the values for f ' and f " were those of Ref. 42.  The values of the 
mass attenuation coefficients are those of Ref. 43. All calculations were performed using 
the SHELXL97 program44  with the exception of 11a, where the teXsan crystallographic 
software package45 was used. 
 
Crystal data for 10. C22H34N2O6, M = 422.52, colorless, plate, crystal dimensions 0.05 × 
0.12 × 0.30 mm, triclinic, space group P
_
,1, Z = 1, reflections for cell determination 
2354, 2θ range for cell determination 4 – 55°, a = 6.0630(5) Å, b = 9.5495(6) Å, c = 
10.7064(9) Å, α = 66.451(3)°, β = 83.228(4)°,  γ  = 71.733(5)°, V = 539.61(7) Å3 , T = 
160 K, Dx = 1.300 g cm-3, µ(MoKα) = 0.0941 mm-1, 2θ (max) = 55°, total reflections 
measured = 11110, symmetry independent reflections = 2457, reflections with I > 2σ (I) = 
1919, reflections used in refinement = 2455, parameters refined = 143, R(F)  [I > 2σ (I) 
reflections] = 0.0473, wR(F2)  [all data] = 0.1277 (w = [σ 2(Fo2) + (0.0624P)2 + 
0.093P]-1 where P = (Fo2 + 2Fc2) / 3), goodness of fit = 1.059, secondary extinction 
coefficient = 0.09(2), final ∆ max /σ = 0.001, ∆ρ (max; min) = 0.30; -0.28e Å-3. 
 
Crystal data for 11a. C17H26N2O3, M = 306.40, colorless, prism, crystal dimensions 0.15 
× 0.15 × 0.25 mm, monoclinic, space group P21/n, Z = 4, reflections for cell 
determination 4110, 2θ range for cell determination 4 – 55°, a = 8.1009(1) Å, b = 
17.1770(3) Å, c = 12.6459(2) Å, β = 101.112(1)°, V = 1726.67(5) Å3 , T = 160 K, Dx = 
1.179 g cm-3, µ(MoKα) = 0.0806 mm-1, 2θ (max) = 55°, total reflections measured = 
37684, symmetry independent reflections = 3973, reflections used in refinement [I > 2σ 
(I)] = 2947, parameters refined = 208, R(F) = 0.0469, wR(F) = 0.0469 (w = [σ 2(Fo) + 
(0.005Fo)2]-1, goodness of fit = 2.962, secondary extinction coefficient = 3.3(5) × 10-6, 
final ∆ max /σ = 0.0005, ∆ρ (max; min) = 0.39; -0.27e Å-3. 
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Crystal data for 12. C30H38N2O6, M = 522.64, colorless, tablet, crystal dimensions 0.05 × 
0.10 × 0.20 mm, monoclinic, space group P21/n, Z = 2, reflections for cell determination 
2439, 2θ range for cell determination 4 – 50°, a = 6.0109(2) Å, b = 17.3238(5) Å, c = 
12.9060(5) Å, β = 91.855(2) °, V = 1343.22(8) Å3 , T = 160 K, Dx = 1.292 g cm-3, 
µ(MoKα) = 0.0896 mm-1, 2θ (max) = 50°, total reflections measured = 17323, symmetry 
independent reflections = 2359, reflections with I > 2σ (I) = 1731, reflections used in 
refinement = 2358, parameters refined = 180, R(F)  [I > 2σ (I) reflections] = 0.0540, 
wR(F2)  [all data] = 0.1283 (w = [σ 2(Fo2) + (0.0395P)2 + 0.6836P]-1 where P = (Fo2 + 
2Fc2) / 3), goodness of fit = 1.129, secondary extinction coefficient = 0.013(2), final 
∆ max /σ = 0.001, ∆ρ (max; min) = 0.35; -0.18e Å-3. 
 
Crystal data for trans-14. C28H34N2O6, M = 494.58, colorless, needle, crystal dimensions 
0.05 × 0.05 × 0.25 mm, monoclinic, space group C2/c, Z = 4, reflections for cell 
determination 2421, 2θ range for cell determination 4 – 50°, a = 18.6829(6) Å, b = 
14.5471(5) Å, c = 10.0381(3) Å, β = 104.943(2)°, V = 2635.9(2) Å3 , T = 160 K, Dx = 
1.246 g cm-3, µ(MoKα) = 0.0875 mm-1, 2θ (max) = 50°, total reflections measured = 
18709, symmetry independent reflections = 2333, reflections with I > 2σ (I) = 1579, 
reflections used in refinement = 2333, parameters refined = 170, R(F)  [I > 2σ (I) 
reflections] = 0.0456, wR(F2)  [all data] = 0.1156 (w = [σ 2(Fo2) + (0.041P)2 + 
1.0127P]-1 where P = (Fo2 + 2Fc2) / 3), goodness of fit = 1.040, secondary extinction 
coefficient = 0.0040(7), final ∆ max /σ = 0.001, ∆ρ (max; min) = 0.18; -0.17e Å-3. 
 
Crystal data for (S,S)-14. C28H34N2O6, M = 494.58, colorless, prism, crystal dimensions 
0.13 × 0.13 × 0.30 mm, monoclinic, space group P21, Z = 4, reflections for cell 
determination 7591, 2θ range for cell determination 4 – 60°, a = 5.4181(2) Å, b = 
35.569(1) Å, c = 13.3108(4) Å,  β = 90.090(1)°, V = 2565.2(2) Å3 , T = 160 K, Dx = 
1.281 g cm-3, µ(MoKα) = 0.0899 mm-1, 2θ (max) = 60°, total reflections measured = 
52489, symmetry independent reflections = 7611, reflections with I > 2σ (I) = 5073, 
reflections used in refinement = 7606, parameters refined = 675, R(F)  [I > 2σ (I) 
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reflections] = 0.0446, wR(F2)  [all data] = 0.0899 (w = [σ 2(Fo2) + (0.036P)2]-1 where P 
= (Fo2 + 2Fc2) / 3), goodness of fit = 1.025, secondary extinction coefficient = 0.012(1), 
final ∆ max /σ = 0.001, ∆ρ (max; min) = 0.23; -0.21e Å-3. 
 
Crystal data for 24. C28H34N2O6, M = 494.58, colorless, prism, crystal dimensions 0.22 
× 0.25 × 0.32 mm, triclinic, space group P
_
,1, Z = 1, reflections for cell determination 
2078, 2θ range for cell determination 4 – 50°, a = 5.9467(3) Å, b = 10.1233(5) Å, c = 
10.9664(5) Å, α = 73.363(3)°, β = 83.818(3)°, γ  = 76.704(3)°, V = 614.97(5) Å3 , T = 
160 K, Dx = 1.335 g cm-3, µ(MoKα) = 0.0938 mm-1, 2θ (max) = 50°, total reflections 
measured = 8138, symmetry independent reflections = 2137, reflections with I > 2σ (I) = 
1796, reflections used in refinement = 2136, parameters refined = 171, R(F)  [I > 2σ (I) 
reflections] = 0.0390, wR(F2)  [all data] = 0.1010 (w = [σ 2(Fo2) + (0.043P)2 + 0.2587P]1 
where P = (Fo2 + 2Fc2) / 3), goodness of fit = 1.067, secondary extinction coefficient = 
0.052(9), final ∆ max /σ = 0.001, ∆ρ (max; min) = 0.18; -0.25e Å-3. 
 
Crystal data for 31. C11H11NO3, M = 205.21, colorless, prism, crystal dimensions 0.10 × 
0.17 × 0.30 mm, monoclinic, space group P21/n, Z = 4, reflections for cell determination 
2470, 2θ range for cell determination 4 – 55°, a = 5.6230(2) Å, b = 8.9884(4) Å, c = 
20.2034(8) Å, β = 93.985(3)°, V = 1018.65(7) Å3 , T = 160 K, Dx = 1.338 g cm-3, 
µ(MoKα) = 0.0982 mm-1, 2θ (max) = 55°, total reflections measured = 21205, symmetry 
independent reflections = 2333, reflections with I > 2σ (I) = 1834, reflections used in 
refinement = 2331, parameters refined = 143, R(F)  [I > 2σ (I) reflections] = 0.0517, 
wR(F2)  [all data] = 0.1359 (w = [σ 2(Fo2) + (0.0581P)2 + 0.2986P]-1 where P = (Fo2 + 
2Fc2) / 3), goodness of fit = 1.107, secondary extinction coefficient = 0.032(6), final 
∆ max /σ = 0.001, ∆ρ (max; min) = 0.21; -0.22e Å-3. 
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